Galectin Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Galectin Therapeutics
GALT Stock  USD 2.78  0.06  2.21%   
Galectin Therapeutics financial statements provide useful quarterly and yearly information to potential Galectin Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Galectin Therapeutics financial statements helps investors assess Galectin Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Galectin Therapeutics' valuation are summarized below:
Market Capitalization
174.5 M
Earnings Share
(0.73)
There are currently one hundred twenty fundamental trends for Galectin Therapeutics that can be evaluated and compared over time across competitors. All traders should confirm Galectin Therapeutics' regular fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 114.5 M in 2024. Enterprise Value is likely to gain to about 104.5 M in 2024
Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 40 M, Interest Expense of 2.7 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Galectin Therapeutics Correlation against competitors.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Galectin Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.9 M28.2 M19.8 M
Slightly volatile
Short and Long Term Debt Total75.4 M71.8 M14.4 M
Slightly volatile
Other Current Liabilities9.7 M9.2 M3.6 M
Slightly volatile
Total Current Liabilities16.5 M15.7 M5.4 M
Slightly volatile
Accounts Payable6.8 M6.4 M1.8 M
Slightly volatile
Cash13.8 M25.7 M18.7 M
Slightly volatile
Non Current Assets Total514.5 K490 K192 K
Slightly volatile
Cash And Short Term Investments14 M25.7 M18.7 M
Slightly volatile
Common Stock Total Equity35.5 K64.4 K36.1 K
Slightly volatile
Common Stock Shares Outstanding63.2 M60.2 M36.4 M
Slightly volatile
Liabilities And Stockholders Equity14.9 M28.2 M19.8 M
Slightly volatile
Other Stockholder Equity308.2 M293.6 M183 M
Slightly volatile
Total Liabilities92.9 M88.4 M21.2 M
Slightly volatile
Total Current Assets14.7 M27.7 M19.6 M
Slightly volatile
Short Term Debt43.7 K46 K40.8 K
Slightly volatile
Common Stock39.3 K61 K36.5 K
Slightly volatile
Property Plant And Equipment Net50.4 K53 K171.1 K
Pretty Stable
Other Current Assets2.2 M2 M1.3 M
Slightly volatile
Property Plant And Equipment Gross137 K74 K206.5 K
Slightly volatile
Current Deferred Revenue53.9 K56.7 K78.5 K
Slightly volatile
Other Liabilities56.4 K59.4 K68.5 K
Slightly volatile
Preferred Stock Total Equity450.6 K474.3 K2.8 M
Slightly volatile
Net Receivables187.2 K210.6 K229.3 K
Slightly volatile
Warrants2.9 M1.6 M3.8 M
Slightly volatile
Capital Surpluse200.2 M301.2 M186 M
Slightly volatile
Net Working Capital20.3 M12 M10.4 M
Slightly volatile
Capital Stock2.7 M2.3 M6.3 M
Slightly volatile
Capital Lease Obligations38.9 K46 K37.8 K
Pretty Stable

Galectin Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.3 M5.9 M5.7 M
Slightly volatile
Other Operating Expenses40 M38.1 M20.2 M
Slightly volatile
Research Development33.7 M32.1 M14.4 M
Slightly volatile
Total Operating Expenses40 M38.1 M20.2 M
Slightly volatile
Preferred Stock And Other Adjustments117.1 K123.3 K620.9 K
Slightly volatile
Interest Income195.3 K186 K76.8 K
Slightly volatile
Selling And Marketing Expenses35.2 K39.6 K43.1 K
Slightly volatile

Galectin Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities42 M40 M18.3 M
Slightly volatile
End Period Cash Flow13.8 M25.7 M18.7 M
Slightly volatile
Begin Period Cash Flow13.2 M18.6 M17.3 M
Slightly volatile
Depreciation38.9 K33 K31 K
Pretty Stable
Stock Based Compensation2.1 M2.3 M2.6 M
Very volatile
Change To Netincome2.3 M2.4 M3 M
Slightly volatile
Net Borrowings8.6 M9 M25.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield0.00160.00170.0094
Slightly volatile
Average Payables157 K211 K222.6 K
Very volatile
Capex To Depreciation0.630.480.4974
Slightly volatile
Payables Turnover0.00490.00511.3952
Slightly volatile
Cash Per Share0.780.42650.5789
Very volatile
Days Payables Outstanding74.7 K71.1 K29 K
Slightly volatile
Income Quality0.90.80270.7662
Slightly volatile
Intangibles To Total Assets1.0E-41.0E-40.0037
Slightly volatile
Current Ratio1.681.76776.1936
Pretty Stable
Graham Number3.373.92172.3662
Pretty Stable
Capex Per Share3.0E-43.0E-46.0E-4
Slightly volatile
Interest Debt Per Share1.31.23510.252
Slightly volatile
Debt To Assets2.672.5441.0048
Slightly volatile
Days Of Payables Outstanding74.7 K71.1 K29 K
Slightly volatile
Ebt Per Ebit0.811.07861.0056
Slightly volatile
Long Term Debt To Capitalization3.726.23831.8892
Slightly volatile
Total Debt To Capitalization6.556.23832.0542
Slightly volatile
Quick Ratio1.681.76776.1936
Pretty Stable
Net Income Per E B T0.810.910.9875
Slightly volatile
Cash Ratio1.561.63695.9991
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.121.151.026
Slightly volatile
Debt Ratio2.672.5441.0048
Slightly volatile

Galectin Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap114.5 M109 M80.1 M
Slightly volatile
Enterprise Value104.5 M99.5 M64.7 M
Slightly volatile

Galectin Fundamental Market Drivers

Cash And Short Term Investments25.7 M

Galectin Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Galectin Therapeutics Financial Statements

Galectin Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue56.7 K53.9 K
Cost Of Revenue33 K31.4 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY